In an increasingly complex and fragmented healthcare space, isn’t it time for the true innovators to take control? Against a backdrop of declining FDA approvals, and the expiration of leading drugs patents in 2017, the next few years in oncology will be volatile. But with volatility comes opportunity—especially for pharmaceutical companies ready to step from the periphery to the center of the healthcare stage.
Back for an 8th year, eyeforpharma’s Oncology Market Access & Pricing Summit brings together all stakeholders to deliver workable solutions to drive better patient outcomes and greater therapy access.
As the spotlight pans from volume to value, Pharma can—and should—shoulder this responsibility, leading stakeholders toward mutually beneficial outcomes, and driving the decision-making processes that will both outline oncology’s future, and redefine the meaning of healthcare.
